# Establishing Best Treatment Strategy for T4 Esophageal Cancer

> **NCT06531434** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cheng-Kung University Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Esophageal Cancer TNM Staging Primary Tumor (T) T4

## Interventions

- **COMBINATION_PRODUCT:** "Docetaxel", "Cisplatin", "fluorouracil", "Radiation"

## Key facts

- **NCT ID:** NCT06531434
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06531434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06531434, "Establishing Best Treatment Strategy for T4 Esophageal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06531434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*